mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.